Clinical trials: Human Factors
Hyperlipidemia
Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans
The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.
- Trial name
- Capros (NCT01858376)
- Testing
- Capros dietary supplement
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chandan K Sen
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Glaucoma, Retinal Disease
The EASE Study - Human Factor and Usability Testing of a Binocular OCT System
Ophthalmology is among the most technology driven of all medical specialties, with advanced medical imaging devices - and specialised computer software - increasingly adopted for routine clinical use.
- Conditions
- Glaucoma, Retinal Disease, Strabismus, Healthy Volunteers
- Trial name
- EASE (NCT02822612)
- Testing
- Binocular OCT prototype
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University College, London
Osteoarthritis of the Knee
Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement
The purpose of this study is to test whether surgical insertion of total knee replacement provides further improvement in quality of life, pain and function in addition to an algorithm for systematic non-surgical treatment…
- Trial name
- MEDIC (NCT01410409)
- Testing
- Neuromuscular training (NEMEX-TJR), Paracetamol, Burana
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Northern Orthopaedic Division, Denmark
Insurance Status/Stability
IMPACCT for Kids' Care
Health insurance is important for children. Public insurance programs are available to many children, but some families report being confused about how to get and keep this insurance.
- Trial name
- IMPACCT (NCT02298361)
- Testing
- Health insurance outreach IT tools
- Volunteers
- 27,251 people, healthy volunteers welcome
- Sponsor
- OCHIN, Inc.
Smoking, Tobacco
Carbon Monoxide Breath Sensor System Performance, Human Factors, and Usability Assessment Conducted in a Single Visit
Prospective, open label, single center clinical study enrolling 70 subjects to study Performance, Human Factors, and Usability for the Carbon Monoxide Breath Sensor System (COBBS)
- Trial name
- NCT03148613
- Testing
- Carbon Monoxide Breath Sensor System (COBSS), Bedfont - Micro+™ Smokerlyzer®
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- David Utley, MD
Cancer
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
- Trial name
- NCT00816361
- Testing
- MEDI-573
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- MedImmune LLC
Hepatitis B, Hepatitis A
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
The focus of this study is to evaluate how risk factors like age, gender, body mass index, smoking, alcohol consumption, etc. can influence immune response when subjects are vaccinated with GSK Biologicals' combined hepatitis…
- Trial name
- NCT00289731
- Testing
- TWINRIX™, Engerix™-B, HAVRIX™
- Where
- 9 sites in Belgium, Czechia and 1 more
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Neuropathy, Diabetic, Neuropathy;Peripheral
Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic…
- Conditions
- Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
- Trial name
- NCT05291975
- Testing
- Erchonia® EVRL™
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Erchonia Corporation
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Advanced Cancer
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
- Trial name
- NCT03369223
- Testing
- BMS-986249, Nivolumab, Ipilimumab
- Where
- 45 sites in United States, Argentina and 9 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis
Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
The purpose of this study is to validate the user interface of TOBI Podhaler by establishing that the product can support safe and effective use for the intended users
- Trial name
- NCT03502070
- Testing
- Tobi Podhaler
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mylan Inc.
Hematologic Malignancy
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
- Trial name
- NCT02880293
- Testing
- melphalan, fludarabine, thiotepa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cystic Fibrosis
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
The purpose of this actual use human factors (HF) study is to validate the approved US TOBI Podhaler Instructions for Use (IFU), by establishing that the IFU effectively communicates the information necessary to achieve safe and…
- Trial name
- NCT02178540
- Testing
- Tobi Podhaler
- Where
- 13 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Influenza, Vaccination
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
The study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications.
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT05009251
- Testing
- Reminder, Risk reduction, Medical records-based recommendation
- Where
- United States
- Volunteers
- 45,061 people
- Sponsor
- National Bureau of Economic Research, Inc.
Anxiety Depression, Disability Physical
Exploratory Study for Toivoa-001 on Human Factors
The Study will evaluate Rauha as an experimental digital therapeutic for persons with Disabilities suffering from anxiety and/or depression.
- Trial name
- NCT06477913
- Testing
- Rauha
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Toivoa Inc
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Breast Cancer Metastatic
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2.
- Trial name
- NCT03321981
- Testing
- Zenocutuzumab, Trastuzumab, Vinorelbine
- Where
- 25 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Merus B.V.
Rheumatoid Arthritis
Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially…
- Trial name
- NCT02682823
- Testing
- AI-1000 G2, Tocilizumab
- Where
- 8 sites in United States
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche